Literature DB >> 3544293

Cyclosporine: immunology, pharmacology and therapeutic uses.

R B Nussenblatt, A G Palestine.   

Abstract

Human and animal investigations since the mid-1970s have demonstrated the effectiveness of cyclosporine (CsA) as an immunosuppressive agent. In the area of transplantation immunity, it has been shown to enhance success of renal, bone marrow, and liver transplantation. Moreover, certain models of autoimmune disease have been effectively treated with CsA, and a number of studies have reported encouraging results with CsA therapy for ocular inflammatory disorders, notably Behçet's disease. The most serious side effects of CsA are nephrotoxicity and hypertension; thus, conservative dosages of the drug and careful monitoring of renal function during treatment are recommended. The purpose of this review is to provide clinicians and researchers with a clear perspective of both the potential benefits and shortcomings of this agent.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3544293     DOI: 10.1016/0039-6257(86)90035-4

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  32 in total

Review 1.  Immunosuppression in uveitis therapy.

Authors:  R N Van Gelder; H J Kaplan
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Systemic cyclosporin A in high failure risk, repeated corneal transplantation.

Authors:  S Rumelt; V Bersudsky; T Blum-Hareuveni; U Rehany
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

3.  Ocular complications associated with cardiac transplantation.

Authors:  F J Wapner; M L Leib; R Drusin; E Rose; B D Srinivasan
Journal:  Trans Am Ophthalmol Soc       Date:  1992

4.  Isolated lichen planus of the conjunctiva.

Authors:  M Pakravan; T R Klesert; E K Akpek
Journal:  Br J Ophthalmol       Date:  2006-10       Impact factor: 4.638

5.  Diagnostic dilemma between intestinal Behçet disease and inflammatory bowel disease with pyoderma gangrenosum.

Authors:  Cem Evereklioglu
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

Review 6.  Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.

Authors:  A J Olyaei; A M de Mattos; W M Bennett
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

7.  A compartmental model for the ocular pharmacokinetics of cyclosporine in rabbits.

Authors:  C Oh; B A Saville; Y L Cheng; D S Rootman
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

8.  Equine eosinophilic keratoconjunctivitis in California: retrospective study of 47 eyes from 29 cases (1993-2017).

Authors:  Kelly E Knickelbein; Daniela Luethy; Sara M Thomasy; Christopher Reilly; Ann R Strom; Mary E Lassaline
Journal:  Vet Ophthalmol       Date:  2019-01-31       Impact factor: 1.644

9.  The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca.

Authors:  Koray Gumus; Dwight H Cavanagh
Journal:  Clin Ophthalmol       Date:  2009-06-02

10.  Production of interleukin-17 in Behcet's disease is inhibited by cyclosporin A.

Authors:  Wei Chi; Peizeng Yang; Xuefei Zhu; Yuqin Wang; Lina Chen; Xiangkun Huang; Xiaoli Liu
Journal:  Mol Vis       Date:  2010-05-19       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.